Engene Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Engene Therapeutics Inc in the third quarter 2026?
Engene Therapeutics Inc recorded a cumulative net loss of $-10 million during 12 months ending in the third quarter 2026, resulting in a negative return on equity (ROE) of -5.07%.

Within the Biotechnology & Pharmaceuticals industry 20 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 138 to 488.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jul 31 2026) III. Quarter	(Apr 30 2026) II. Quarter	(Jan 31 2026) I. Quarter	(Oct 31 2025) IV. Quarter	(Jul 31 2025) III. Quarter
Y / Y Equity Change	14.76 %	12.26 %	-38.48 %	-38.48 %	-
Y / Y Net Income Change	-	-	20.86 %	-	104.91 %
Net Income (TTM) in Millions	-10	51	-5	-10	43
Return On Equity (TTM)	-5.07 %	25.83 %	-2.59 %	-4.65 %	17.71 %
ENGN's Total Ranking	# 488	# 138	# 90	# 138	# 253
Equity (TTM) in Millions	230	255	168	168	201
Seq. Equity Change	-9.75 %	52.15 %	0 %	-16.43 %	-11.71 %
Seq. Net Income Change	-	1.6 %	-	-	-

Back to ENGN Management Effectiveness >> ENGN's 5 Years Annual ROE >> Compare ENGN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 21
Sector	# 214
Overall	# 488

Return On Equity Statistics
High	Average	Low
27.12 %	12.07 %	-5.07 %
(Jan 31 2025)		(Jul 31 2026)

ENGN Annual Return On Equity	(Oct 31 2025) 2025	(Oct 31 2024) 2024	(Oct 31 2023) 2023
Total Equity in Millions	168	273	72	0	0
Y / Y Equity Change	-38.48 %	276.09 %	-	-	-
Net Income in Millions	117	55	110	0	0
Y / Y Net Income Change	112.73 %	-49.67 %	-	-	-
Return On Equity	69.94 %	20.23 %	151.15 %	-	-

Back to ENGN Management Effectiveness >> ENGN's 5 Years Annual ROE >> Compare ENGN ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 69.94 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ENGN's' Return on Equity at Yahoo Finance
ENGN's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ENGN's Competitors
Subscribers only: Roe for Engene Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for ENGN's Customers

Companies with similar Return On Equity at Jul 31 2026, within Healthcare Sector

ROE

Date modified: 2026-09-10T01:27:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.